0000950170-24-108233.txt : 20240919 0000950170-24-108233.hdr.sgml : 20240919 20240919200231 ACCESSION NUMBER: 0000950170-24-108233 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240917 FILED AS OF DATE: 20240919 DATE AS OF CHANGE: 20240919 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sommadossi Jean-Pierre CENTRAL INDEX KEY: 0001296995 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39661 FILM NUMBER: 241311515 MAIL ADDRESS: STREET 1: 125 SUMMER STREET STREET 2: 16TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Atea Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001593899 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 460574869 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 225 FRANKLIN STREET STREET 2: SUITE 2100 CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 857-204-8109 MAIL ADDRESS: STREET 1: 225 FRANKLIN STREET STREET 2: SUITE 2100 CITY: BOSTON STATE: MA ZIP: 02110 4 1 ownership.xml 4 X0508 4 2024-09-17 0001593899 Atea Pharmaceuticals, Inc. AVIR 0001296995 Sommadossi Jean-Pierre 225 FRANKLIN STREET SUITE 2100 BOSTON MA 02110 true true false false President, CEO, and Chairman true Common Stock 2024-09-17 4 S false 33941 4.0458 D 5890053 I Held by JPM Partners LLC Common Stock 2024-09-18 4 S false 22187 4.0325 D 5867866 I Held by JPM Partners LLC Common Stock 2024-09-19 4 S false 1841 4.0019 D 5866025 I Held by JPM Partners LLC Common Stock 116557 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.00 to $4.14. The Reporting Person undertakes to provide Atea Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.00 to $4.0975. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.00 to $4.01. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. All transactions reported herein were made pursuant to a Rule 10b5-1 trading plan dated March 4, 2024. /s/ Andrea Corcoran, as Attorney-in-Fact for Jean-Pierre Sommadossi 2024-09-19